Member Comments are provided by individuals and reflect their personal opinions only. Under NO circumstances should you act on any advice or opinion posted in this forum. ALWAYS check with your personal physician before taking any action regarding your health! MedHelp International and our partners, sponsors and affiliates have no obligation to monitor any comments posted on this site, or the content and/or accuracy of such exchanges. MedHelp International does not endorse the views of any user.
TI Use of chemotherapy plus a monoclonal antibody against HER2 for metastaticMetastatic brain tumor Metastatic cancer to the lung breast cancer that overexpresses HER2.
AU Slamon DJ; Leyland-Jones B; Shak S; Fuchs H; Paton V; Bajamonde A; Fleming T; Eiermann W; Wolter J; Pegram M; Baselga J; Norton L
SO N Engl J Med 2001 Mar 15;344(11):783-92.
is the study that raised concerns about cardiomyopathy with the addition of trastuzumab to anthracycline-based chemotherapy (e.g. adriamycin).
Buzdar, AU, Hunt, K, Smith, T, et al. Significantly higher pathological complete remission rate following neoadjuvant therapy with trastuzumab, paclitaxel, and anthracycline-containing chemotherapy: initial results of a randomized trial in operable breast cancer with Her2 positive disease (abstract). Proc Am Soc Clin Oncol 2004; 22:7s.
is the study that challenges those early findings, and because of this more recent study, some women are receiving this combination ONLY in the setting of a clinical trial.
I had AC, 4 treatments, starting November of 2001. In May of 2004 I was diagnosed with Congestive Heart Failure. Considering the cardiomyopathy/chf is treatable, and in my case reversible, I think I wouldn't care and would go for the best chance possible on hitting the mets. But that is hindsight from someone NOT dealing with it.
AU Slamon DJ; Leyland-Jones B; Shak S; Fuchs H; Paton V; Bajamonde A; Fleming T; Eiermann W; Wolter J; Pegram M; Baselga J; Norton L
SO N Engl J Med 2001 Mar 15;344(11):783-92.
is the study that raised concerns about cardiomyopathy with the addition of trastuzumab to anthracycline-based chemotherapy (e.g. adriamycin).
Buzdar, AU, Hunt, K, Smith, T, et al. Significantly higher pathological complete remission rate following neoadjuvant therapy with trastuzumab, paclitaxel, and anthracycline-containing chemotherapy: initial results of a randomized trial in operable breast cancer with Her2 positive disease (abstract). Proc Am Soc Clin Oncol 2004; 22:7s.
is the study that challenges those early findings, and because of this more recent study, some women are receiving this combination ONLY in the setting of a clinical trial.